Buoyed by a Texas court precedent limiting the testimony that plaintiffs can elicit from chairmen of a corporation they sue, American Home Products is trying to close the door on the remaining litigation over its diet drug fen-phen.

The Madison, N.J.-based company succeeded in blocking temporarily the depositions of chairman and CEO Jack Stafford and Dr. Bruce Burlington, AHP’s Food and Drug Administration expert, which were scheduled for today in Kerr v. Wyeth-Ayerst Laboratories, 98-07-02570E, a suit on behalf of two Houston women, Berle Dee Kerr and Dora Barton, who claim to have developed valvular heart disorders from using the diet drug. Trial has been set for March before District Court Judge Frederick Edwards, in Conroe, Texas.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]